Prelude therapeutics reports second quarter 2024 financial results and provides corporate update

Interim phase 1 data for its first-in-class, highly selective iv smarca2 degrader, prt3789, selected for an oral presentation at the european society for medical oncology (esmo) congress 2024 in september

PRLD Ratings Summary

PRLD Quant Ranking